Status: Recruiting
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
Participants needed: 159
Trial details
Phase: Phase 3Age: 18-79Biological sex: AllType: InterventionalSponsor: AmgenUpdated: Oct 1, 2026Locations: 4
Eligibility criteria
Adults aged ≥18 years and <80 years. [+5]
Secondary membranous nephropathy (e.g., due to autoimmune disease, infection, ma... [+6]